First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014 - Concepedia

Concepedia

Publication | Closed Access

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

126

Citations

21

References

2015

Year

Bristi Basu, Emma Dean, M. Puglisi, Alastair Greystoke, Michael Ong, Wendy Burke, Maria Cavallin, Graham Bigley, Christopher J. Womack, Elizabeth A. Harrington,

Clinical Cancer Research

Abstract

The recommended phase II dose for further evaluation of AZD2014 is 50 mg twice daily, and at this dose it has been possible to demonstrate pharmacologically relevant plasma concentrations, target inhibition in tumor, and clinical responses.

References

	Year	Citations

Page 1